• HEY2 Biology Meets T7 RNA Polymerase

  2026-08-24

  The HEY2–HDAC1 regulatory module links cardiac energy failure to transcriptional control. This thought-leadership article explains how T7 RNA Polymerase can help translational researchers convert such mechanistic insights into controlled RNA-based experiments while clarifying the boundaries between platform utility and therapeutic evidence.

• NVP-BGJ398 Phosphate: FGFR Research Guide

  2026-08-24

  NVP-BGJ398 phosphate is a potent FGFR1–3 inhibitor for studying altered FGFR signaling in cancer and skeletal disease models. Supplier-reported biochemical IC50 values are 0.9 nM for FGFR1, 1.4 nM for FGFR2, and 1 nM for FGFR3, while peer-reviewed mouse data support pharmacological inhibition of FGFR3 signaling in SLC26A2-related chondrodysplasia.

• C8-HSL: From Quorum Sensing to Cancer Biology

  2026-08-23

  N-octanoyl-L-Homoserine lactone is evolving from a quorum-sensing reagent into a translational probe for connecting bacterial communication with host-cell signaling. This thought-leadership guide examines the PI3K/AKT/ERK evidence, proposes validation workflows, and outlines responsible paths toward infection biology and cancer–microbiota research.

• Temafloxacin Activity Against Gram-Positive Bacteria

  2026-08-22

  The reference study combined new broth-microdilution data with a literature review to define temafloxacin’s enhanced in-vitro activity against clinically important Gram-positive cocci. Its findings support strong activity against Staphylococcus aureus and Streptococcus pneumoniae while also showing how pH, serum, magnesium, urine, and inoculum conditions can affect interpretation.

• GSK 2837808A: LDHA Inhibition Workflow

  2026-08-22

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for dissecting lactate production, glucose consumption, and tumor–immune signaling. This workflow translates its biochemical selectivity into practical cell-based assays for cancer metabolism research while addressing exposure, solubility, and pathway-specific interpretation.

• MRT68921: Turning Autophagy Off to See It Clearly

  2026-08-21

  Autophagy research is moving from descriptive imaging toward causal pathway analysis. This thought-leadership article explains how MRT68921, a dual ULK1/2 inhibitor, can help translational researchers connect ULK signaling with lipid metabolism, ATG13 phosphorylation, and LC3 flux while maintaining appropriate preclinical boundaries.

• Astrocytic GAT-3 Controls Dentate Gyrus Memory

  2026-08-20

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than simply a GABA clearance system. Combining electrophysiology, optogenetics, calcium signaling analysis, immunohistochemistry, and contextual fear assays, the authors connect GAT-3-dependent astrocytic Ca2+ signaling with GluN2B-NMDAR-mediated excitation and memory formation.

• Gut-Brain Cholinergic Signaling in Epilepsy

  2026-08-20

  Jia et al. identify a microbiota–vagus–brain cholinergic circuit through which oral Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a pediatric refractory epilepsy trial. The study links colonic ChAT-positive cells, vagal transmission, and Lactobacillus enrichment, providing a mechanistic framework for microbiota-targeted epilepsy research.

• Nonivamide: TRPV1 Assay Design Beyond Cancer

  2026-08-19

  Nonivamide is a capsaicin analog that connects TRPV1 pharmacology with cancer cell growth inhibition and neuroimmune assay design. This article explains how to distinguish direct apoptosis from circuit-level inflammation effects and how to build more interpretable workflows.

• Puromycin Dihydrochloride: Assay Logic

  2026-08-19

  Puromycin dihydrochloride is more than a selection reagent: it is a mechanistic probe for translation, ribosome behavior, and experimental confounding. This article shows how to separate antibiotic selection from phenotype measurement, using telomere biology research as a model for better assay design.

• Prochlorperazine: From Antiemesis to Assay Logic

  2026-08-18

  Prochlorperazine is a dopamine D2 receptor antagonist with applications spanning antiemetic therapy and experimental melanoma research. This article develops a temporal, mechanism-aware framework for translating its pharmacology into more interpretable cell-based assays.

• ARCA Cy3 EGFP mRNA (5-moUTP): Cell Assays

  2026-08-18

  This scenario-driven guide shows how ARCA Cy3 EGFP mRNA (5-moUTP), SKU R1008, can separate mRNA uptake, intracellular trafficking, translation, and assay-related cytotoxicity in mammalian cell workflows. It combines practical handling parameters with evidence-based interpretation and vendor-selection criteria.

• Palmitic acid: Practical Protocol and QC Guide

  2026-08-17

  Palmitic acid (SKU N2456), also known as hexadecanoic acid, provides a characterized saturated long-chain fatty acid for controlled studies of lipid metabolism, protein palmitoylation, metabolic disorder research, and inflammation signaling studies. It is intended for solvent-based preparation rather than direct aqueous dissolution or long-term solution storage, so matched vehicle controls and prompt use are essential.

• Oxaliplatin Workflows for Resistance Research

  2026-08-17

  Build more reproducible Oxaliplatin assays by combining controlled DNA-damage exposure, resistance modeling, organoid validation, and mechanism-aware combination testing. This workflow translates evidence on CDK1, PARP1, and olaparib sensitivity into practical choices for cancer chemotherapy research.

• Cell lysis buffer for WB and IP in CAF Studies

  2026-08-16

  Cell lysis buffer for WB and IP can support mechanistic studies of cancer-associated fibroblast signaling by combining non-denaturing extraction with protease and phosphatase inhibition. This guide translates the ANGPTL4-IQGAP1 prostate cancer findings into practical decisions for Western blotting, immunoprecipitation, co-IP, and ELISA.

7853 records 1/524 page Next 12345 下5页 Last page